← All comparisons
Head-to-head · FAERS comparison

Adalimumab vs Adalimumab-Adaz: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

AdalimumabAdalimumab-Adaz
Drug class–Tumor Necrosis Factor Blocker
Brand namesHumiraAdalimumab
FAERS reports703,38952,421
Serious51%93%
Death outcome30,0458,010
Boxed warningYes WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may leadYes SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adaz, are at increased risk for developing

Signals both drugs share

ReactionAdalimumabAdalimumab-AdazLabel screen (A / B)
Duodenal ulcer perforation4,928 · PRR 60.42,968 · PRR 273.0Labeled (related wording) / Labeled (related wording)
Muscle injury3,785 · PRR 24.92,233 · PRR 149.7Labeled (related wording) / Labeled (related wording)
Pemphigus9,240 · PRR 86.73,946 · PRR 186.5Not in label — unassessed / Not in label — unassessed
Hand deformity8,490 · PRR 54.53,773 · PRR 162.4Not in label — unassessed / Not in label — unassessed
Helicobacter infection5,291 · PRR 31.52,985 · PRR 165.9Not in label — unassessed / Not in label — unassessed
Folliculitis4,615 · PRR 23.52,836 · PRR 151.6Not in label — unassessed / Not in label — unassessed
Rheumatic fever3,220 · PRR 83.82,392 · PRR 490.1Likely indication confounding / Likely indication confounding
Facet joint syndrome1,918 · PRR 45.61,757 · PRR 510.1Not in label — unassessed / Not in label — unassessed
Bone erosion2,023 · PRR 39.0866 · PRR 129.5Not in label — unassessed / Not in label — unassessed
Deep vein thrombosis postoperative1,428 · PRR 79.91,171 · PRR 602.2Not in label — unassessed / Not in label — unassessed
Dislocation of vertebra1,248 · PRR 37.4944 · PRR 296.6Not in label — unassessed / Not in label — unassessed
Adjustment disorder with depressed mood1,172 · PRR 40.7956 · PRR 363.7Not in label — unassessed / Not in label — unassessed
Lupus vulgaris888 · PRR 87.9865 · PRR 1,097.8Not in label — unassessed / Not in label — unassessed
Retinitis809 · PRR 27.4778 · PRR 351.8Not in label — unassessed / Not in label — unassessed

Labeled signals distinctive to Adalimumab

Labeled signals distinctive to Adalimumab-Adaz

Common questions

Which has more reported side effects, Adalimumab or Adalimumab-Adaz?

Adalimumab has 703,389 FAERS reports and Adalimumab-Adaz 52,421. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (51% vs 93%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Adalimumab and Adalimumab-Adaz share?

Both drugs carry disproportionality signals for duodenal ulcer perforation, muscle injury, pemphigus, hand deformity, helicobacter infection. Shared signals often reflect a shared drug class or the condition both are used for.

Is Adalimumab or Adalimumab-Adaz safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.